The Technical Analyst
Prelude Therapeutics [PRLD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Prelude Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
-17.70% $3.44
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 233.13 mill |
| EPS: | -2.02 |
| P/E: | -1.700 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 67.77 mill |
| Avg Daily Volume: | 0.0683 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.700 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.29x |
| Company: PE -1.700 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.139 (-95.95%) $-3.30 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.08 - 3.80 ( +/- 10.35%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-04 | Huang Jane | Sell | 9 375 | Restricted Stock Unit |
| 2024-04-04 | Huang Jane | Buy | 9 375 | Common Stock |
| 2024-04-04 | Huang Jane | Sell | 3 347 | Common Stock |
| 2024-03-01 | Lim Bryant David | Buy | 150 000 | Employee Stock Option (right to buy) |
| 2024-03-01 | Scherle Peggy | Buy | 150 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 99.32 |
| Last 98 transactions |
| Buy: 26 942 964 | Sell: 353 466 |
Forecast:
16:00 - $3.44
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.44
Forecast 2: 16:00 - $3.44
Forecast 3: 16:00 - $3.44
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.44 (-17.70% ) |
| Volume | 0.112 mill |
| Avg. Vol. | 0.0683 mill |
| % of Avg. Vol | 164.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PRLD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Last 10 Buy Signals
Latest Press Releases
2024-04-09 16:35:00 - Press Release
Prelude Highlights Continued Strength Of Discovery Engine At 2024 Aacr Annual Meeting
Highly selective oral smarca2 degrader, prt7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses
2024-03-05 16:45:00 - Press Release
Prelude Announces Acceptance Of Multiple Preclinical Abstracts At The 2024 Aacr Annual Meeting
Wilmington, del., march 05, 2024 (globe newswire) -- prelude therapeutics incorporated (nasdaq: prld), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the company's highly selective oral smarca2 degrader, its potentially best-in-class cdk9 inhibitor and its next-generation cdk4/6 inhibitor, have been accepted for presentation at the american association for cancer research (aacr) annual meeting 2024, taking place from april 5 to 10, 2024.
2024-02-29 16:05:00 - Press Release
Prelude Therapeutics To Participate In Barclays Global Healthcare Conference
Wilmington, del., feb. 29, 2024 (globe newswire) -- prelude therapeutics incorporated (prelude) (nasdaq: prld), a clinical-stage precision oncology company, announced today that the company will participate in the barclays global healthcare conference in miami, march 12-14, 2024.
2024-02-15 16:05:00 - Press Release
Prelude Therapeutics Reports Full Year 2023 Financial Results And Outlines Key Objectives For 2024
First-in-class iv smarca2 degrader and potentially best-in-class cdk9 inhibitor on track to generate potential proof-of-concept data in 2024
2023-12-11 09:34:00 - Press Release
Prelude Therapeutics Announces $25 Million Private Placement
Wilmington, del., dec. 11, 2023 (globe newswire) -- prelude therapeutics incorporated (nasdaq: prld) (“prelude” or the “company”), a clinical-stage precision oncology company, today announced a private placement that the company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the company. proceeds from the private placement will be used to primarily fund the continued advancement of its smarca2 portfolio, for working capital and general corporate purposes.
Latest News
2024-02-29 16:05:00 - GlobeNewsWire
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024.
2024-01-25 07:41:08 - Zacks Investment Research
New Strong Buy Stocks for January 25th
S, ASAN, PRLD, EMKR and SNAP have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023.
2023-10-04 13:31:20 - Zacks Investment Research
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-04-27 08:30:00 - GlobeNewsWire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences.
2023-04-11 08:30:00 - GlobeNewsWire
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline
2023-03-18 18:48:06 - InvestorPlace
The 7 Worst Stocks to Buy Now
Generally, I dislike writing about the worst stocks to buy now (or similar themes) because it invariably offends members of the internet defense league. It's not the greatest experience to receive a flood of messages from people defending the honor of corporations who could care less about them.
2023-03-16 13:46:15 - Zacks Investment Research
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.
2023-02-09 09:05:00 - GlobeNewsWire
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.
2022-08-10 10:32:18 - Zacks Investment Research
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
Prelude Therapeutics (PRLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2022-06-22 11:35:22 - Zacks Investment Research
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 169.5% in Prelude Therapeutics Incorporated (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.